全文获取类型
收费全文 | 287033篇 |
免费 | 6917篇 |
国内免费 | 365篇 |
专业分类
耳鼻咽喉 | 2894篇 |
儿科学 | 10607篇 |
妇产科学 | 6112篇 |
基础医学 | 31264篇 |
口腔科学 | 4947篇 |
临床医学 | 20472篇 |
内科学 | 57589篇 |
皮肤病学 | 4659篇 |
神经病学 | 25749篇 |
特种医学 | 11672篇 |
外国民族医学 | 30篇 |
外科学 | 43880篇 |
综合类 | 2934篇 |
一般理论 | 24篇 |
预防医学 | 27708篇 |
眼科学 | 4710篇 |
药学 | 16692篇 |
中国医学 | 1014篇 |
肿瘤学 | 21358篇 |
出版年
2023年 | 793篇 |
2022年 | 1469篇 |
2021年 | 3084篇 |
2020年 | 1665篇 |
2019年 | 2880篇 |
2018年 | 25100篇 |
2017年 | 19383篇 |
2016年 | 21694篇 |
2015年 | 3406篇 |
2014年 | 4568篇 |
2013年 | 5961篇 |
2012年 | 13954篇 |
2011年 | 28085篇 |
2010年 | 22807篇 |
2009年 | 15201篇 |
2008年 | 24985篇 |
2007年 | 27261篇 |
2006年 | 6434篇 |
2005年 | 8090篇 |
2004年 | 8698篇 |
2003年 | 9354篇 |
2002年 | 7250篇 |
2001年 | 3623篇 |
2000年 | 3853篇 |
1999年 | 3061篇 |
1998年 | 1186篇 |
1997年 | 940篇 |
1996年 | 735篇 |
1995年 | 666篇 |
1994年 | 555篇 |
1993年 | 498篇 |
1992年 | 1382篇 |
1991年 | 1410篇 |
1990年 | 1326篇 |
1989年 | 1123篇 |
1988年 | 985篇 |
1987年 | 946篇 |
1986年 | 866篇 |
1985年 | 827篇 |
1984年 | 596篇 |
1983年 | 535篇 |
1982年 | 364篇 |
1979年 | 507篇 |
1978年 | 363篇 |
1975年 | 380篇 |
1974年 | 432篇 |
1973年 | 434篇 |
1972年 | 375篇 |
1970年 | 378篇 |
1969年 | 369篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Maite Cruz Piqueras Ainhoa Rodríguez García de Cortazar Joaquín Hortal Carmona Javier Padilla Bernáldez 《Gaceta sanitaria / S.E.S.P.A.S》2019,33(1)
Objective
To analyse and understand vaccination hesitancy discourses, particularly those of people who have decided not to vaccinate their sons and daughters.Methods
Qualitative study of five individual interviews and two focus groups with people who chose not to vaccinate their children in the province of Granada (Spain).Results
Mothers and fathers manifest a system of health beliefs different to the biomedical paradigm. From an ethical point of view, they justify their position based on the right to autonomy and responsibility for their decisions. Alleged specific reasons: they doubt administration of several vaccines simultaneously at an early age in a systematic way and without individualising each case; they fear adverse effects and do not understand the variations of the vaccination schedule.Conclusions
These vaccination hesitancy discourses respond to the individual vs collective conflict; parents defend their right to bring up their children without any interference from the state and focus their responsibility on the individual welfare of their sons and daughters, regardless of the consequences that their actions might have on the collective. In their management of risks, they consider those derived from vaccination more relevant than the individual or collective consequences of not doing so. The vaccines generating most doubts are the more controversial ones within the scientific world. Transparency in communication of adverse effects; authorities respect for other health/disease concepts; banishment of the term “anti-vaccines” from the media and scientific vocabulary, and developing spaces for dialogue are bridges to be built. 相似文献3.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
4.
Irmak Karaca Suzan Güven Yılmaz Melis Palamar Halil Ateş 《Ocular immunology and inflammation》2020,28(6):947-951
ABSTRACT
Purpose
To investigate the effect of 1% tropicamide on anterior chamber aqueous flare (ACAF) measurements acquired with laser flare meter in patients with pseudoexfoliation. 相似文献5.
6.
7.
Özlem Keskin Ayfer Tuncer Gonul Adalioglu Bulent E. Sekerel Cansn Saçkesen Omer Kalayc 《Pediatric allergy and immunology》2006,17(6):396-407
Allergoid immunotherapy is a new form of allergen immunotherapy allowing safe administration of high allergen doses. There is limited information on the effects of allergoid immunotherapy in children with allergic rhinitis. To investigate the immunological and clinical effects of allergoid immunotherapy in children with allergic rhinitis due to grass pollen allergy. Children with allergic rhinitis were assigned to allergoid immunotherapy (n = 27) or control (n = 26, no immunotherapy) groups. Children in the immunotherapy group received seven injections of grass pollen allergoid immunotherapy before grass pollen season and continued to receive maintenance immunotherapy for 27 months. All patients were offered a pharmacotherapy regimen to be used on demand during the pollen seasons. Clinical and laboratory parameters were compared between the immunotherapy and control groups. The rhinoconjunctivitis symptom-medication score and asthma symptom score were lower in the immunotherapy group after 1 yr of maintenance immunotherapy (p < 0.01 for both). Skin test reactivity and nasal reactivity as determined by nasal provocation testing for grass pollen were significantly decreased after 1 yr of immunotherapy (p < 0.001 for both). The seasonal increase in bronchial reactivity and nasal lavage eosinophil cationic protein levels were prevented after the first year of immunotherapy (p < 0.05 for both). The seasonal increase in immunoglobulin (Ig)E decreased (p < 0.05) and grass-specific IgG, IgG(1) and IgG(4) increased significantly already at the end of the seven-injection build-up therapy (p < 0.001, for all). Interleukin (IL)-4 levels in the culture supernatants showed a steady decline from baseline at first and second year of immunotherapy (p < 0.001) but remained unchanged in the control group. Allergoid immunotherapy is an effective method in the treatment of grass pollen-induced allergic rhinitis in children and prevents the seasonal increase in bronchial hyper-reactivity. Changes in specific IgE and IgG levels and decreased IL-4 production in peripheral blood mononuclear cell culture supernatants may account for the observed clinical effects. 相似文献
8.
9.
Dolores Herreros Mariano García-Arranz Isabel Pascual Damián García-Olmo 《Experimental dermatology》2006,15(6):482-482
Purpose: To evaluate all consecutive patients treated with infliximab for hidradenitis suppurativa (HS).
Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n = 1), moderate ( n = 4) or null ( n = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n = 2), moderate ( n = 2) or null ( n = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS. 相似文献
Patients and methods: Within 1 year, all consecutive patients seen in our department for HS (1) resistant to usual medical therapies (2) which could not be easily cured by surgery (3) not treated with new medication within 2 months before inclusion were treated intravenously with infliximab (5 mg/kg) without corticosteroids premedication. Four infusions were planned (week 0, week 2, week 6 and week 10) before the interruption of therapy and follow-up. Clinical activity of HS and quality of life of the patients were assessed immediately before the first, the third and the fourth infusions of infliximab.
Results: Seven patients were included. Five completed the four infusions. Two patients received only three infusions because of severe side effects. The Sartorius score moderately improved with infliximab (mean score at week 0: 94 ± 39, at week 6: 71 ± 38 and at week 10: 83 ± 48). At week 6, patients judged the efficacy of therapy as marked ( n = 1), moderate ( n = 4) or null ( n = 2). At week 10, five patients were evaluated and judged this efficacy as marked ( n = 2), moderate ( n = 2) or null ( n = 1). The mean Skindex-29 score varied from 22 ± 11 (E: 25 ± 9, S: 13 ± 5, F: 28 ± 12) at week 0 to 18 ± 10 (E: 22 ± 8, S: 12 ± 8, F: 22 ± 12) at week 10.
Conclusion: The efficacy of infliximab in severe HS is partial. More experience is needed before finding a place for infliximab in the therapeutic armamentarium for HS. 相似文献
10.